Journal of the American Academy of Dermatology · 2019
Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Polansky Maxim, Eisenstadt Rachel, DeGrazia Taryn, Zhao Xiwen, Liu Yuan, Feldman Ron
Аннотация
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune blistering disease requiring treatment with immunosuppressive medications; however, finding a therapy that has a sustained durable response and an acceptable side effect profile has been challenging.
OBJECTIVE: Our study aimed to evaluate the clinical outcomes of patients with BP treated with rituximab therapy at a single academic center.
METHODS: A retrospective chart review was performed on 20 patients who received at least 1 dose of rituximab therapy, either as initial therapy for severe BP or as therapy for recalcitrant disease after having failed conventional immunotherapies.
RESULTS: Within our cohort, 75% of patients (n = 15) achieved remission an average of 169 days following rituximab therapy. There were no rituximab-related deaths and significantly fewer adverse events following rituximab therapy.
LIMITATIONS: This study was limited by its retrospective nature, focus on a single academic center, and small sample size.
CONCLUSION: Use of rituximab therapy demonstrated high rates of remission, steroid-sparing activity, and an acceptable safety profile in our cohort of patients with severe BP or disease refractory to conventional therapies.
OBJECTIVE: Our study aimed to evaluate the clinical outcomes of patients with BP treated with rituximab therapy at a single academic center.
METHODS: A retrospective chart review was performed on 20 patients who received at least 1 dose of rituximab therapy, either as initial therapy for severe BP or as therapy for recalcitrant disease after having failed conventional immunotherapies.
RESULTS: Within our cohort, 75% of patients (n = 15) achieved remission an average of 169 days following rituximab therapy. There were no rituximab-related deaths and significantly fewer adverse events following rituximab therapy.
LIMITATIONS: This study was limited by its retrospective nature, focus on a single academic center, and small sample size.
CONCLUSION: Use of rituximab therapy demonstrated high rates of remission, steroid-sparing activity, and an acceptable safety profile in our cohort of patients with severe BP or disease refractory to conventional therapies.
Предметные рубрики MeSH
Academic Medical CentersAdultAntibodies, MonoclonalCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGeorgiaHumansKaplan-Meier EstimateMaleMiddle AgedPemphigoid, BullousRetrospective StudiesRisk AssessmentRituximabSeverity of Illness IndexTime FactorsTreatment Outcome